• Je něco špatně v tomto záznamu ?

Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic

T. Pavlík, J. Jarkovský, O. Šanca, M. Koziar Vašáková, P. Dlouhý, V. Černý, P. Štourač, V. Válek, L. Dušek

. 2024 ; 11 (12) : ofae685. [pub] 20241120

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002020

BACKGROUND: We examined the clinical effectiveness of molnupiravir in reducing deaths in a real-world cohort of adult patients with COVID-19 during the Omicron outbreak. METHODS: This was a population-wide retrospective cohort study in the Czech Republic. We analyzed all 74 541 patients with an officially registered diagnosis of SARS-CoV-2 infection between 1 January and 31 December 2022, aged 18 years or older, treated with molnupiravir. The primary outcome was 30-day all-cause mortality; the secondary outcome was 30-day COVID-19-related mortality. Hazard ratios (HRs) were estimated using stratified Cox regression and the Fine-Gray model. RESULTS: The use of molnupiravir in adult SARS-CoV-2 positive patients was associated with a lower risk of both 30-day all-cause mortality: adjusted HR 0.58 (95% confidence interval, 0.53-0.64; P < .001) and 30-day COVID-19-related mortality: adjusted HR 0.50 (95% confidence interval, 0.42-0.58; P < .001). The effect of molnupiravir was highly significant regardless of sex, Deyo-Charlson Comorbidity Index score, hospitalization status, COVID-19 vaccination status, and patients older than age 65 years. CONCLUSIONS: In this cohort study, early initiation of molnupiravir was associated with a significant reduction in 30-day all-cause and COVID-19-related mortality in adult SARS-CoV-2 positive patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002020
003      
CZ-PrNML
005      
20250123101939.0
007      
ta
008      
250117s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ofid/ofae685 $2 doi
035    __
$a (PubMed)39660016
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pavlík, Tomáš $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Data Analysis, Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic $1 https://orcid.org/000000017166032X
245    10
$a Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic / $c T. Pavlík, J. Jarkovský, O. Šanca, M. Koziar Vašáková, P. Dlouhý, V. Černý, P. Štourač, V. Válek, L. Dušek
520    9_
$a BACKGROUND: We examined the clinical effectiveness of molnupiravir in reducing deaths in a real-world cohort of adult patients with COVID-19 during the Omicron outbreak. METHODS: This was a population-wide retrospective cohort study in the Czech Republic. We analyzed all 74 541 patients with an officially registered diagnosis of SARS-CoV-2 infection between 1 January and 31 December 2022, aged 18 years or older, treated with molnupiravir. The primary outcome was 30-day all-cause mortality; the secondary outcome was 30-day COVID-19-related mortality. Hazard ratios (HRs) were estimated using stratified Cox regression and the Fine-Gray model. RESULTS: The use of molnupiravir in adult SARS-CoV-2 positive patients was associated with a lower risk of both 30-day all-cause mortality: adjusted HR 0.58 (95% confidence interval, 0.53-0.64; P < .001) and 30-day COVID-19-related mortality: adjusted HR 0.50 (95% confidence interval, 0.42-0.58; P < .001). The effect of molnupiravir was highly significant regardless of sex, Deyo-Charlson Comorbidity Index score, hospitalization status, COVID-19 vaccination status, and patients older than age 65 years. CONCLUSIONS: In this cohort study, early initiation of molnupiravir was associated with a significant reduction in 30-day all-cause and COVID-19-related mortality in adult SARS-CoV-2 positive patients.
590    __
$a NEINDEXOVÁNO
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jarkovský, Jiří $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Data Analysis, Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic
700    1_
$a Šanca, Ondřej $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Data Analysis, Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic
700    1_
$a Koziar Vašáková, Martina $u Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000204249941 $7 xx0104496
700    1_
$a Dlouhý, Pavel $u Department of Infectious Diseases, Masaryk Hospital in Ústí and Labem, Ústí and Labem, Czech Republic
700    1_
$a Černý, Vladimír $u Department of Anesthesiology, Resuscitation and Intensive Medicine, Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic $u Department of Anaesthesia and Intensive Care Medicine, Charles University in Prague, 3rd Faculty of Medicine, Prague, Czech Republic $1 https://orcid.org/0000000308347650
700    1_
$a Štourač, Petr $u Department of Simulation Medicine, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Paediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno and Medical Faculty of Masaryk University, Brno, Czech Republic
700    1_
$a Válek, Vlastimil $u Minister of Health, Ministry of Health of the Czech Republic, Prague, Czech Republic $u Department of Radiology and Nuclear Medicine, University Hospital Brno and Medical Faculty of Masaryk University, Prague, Czech Republic
700    1_
$a Dušek, Ladislav $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Data Analysis, Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic
773    0_
$w MED00188131 $t Open forum infectious diseases $x 2328-8957 $g Roč. 11, č. 12 (2024), s. ofae685
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39660016 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123101933 $b ABA008
999    __
$a ok $b bmc $g 2254445 $s 1238023
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 11 $c 12 $d ofae685 $e 20241120 $i 2328-8957 $m Open forum infectious diseases $n Open Forum Infect Dis $x MED00188131
LZP    __
$a Pubmed-20250117

Najít záznam

Citační ukazatele

Možnosti archivace